Inhibition of DYRK1A and GSK3B induces human β-cell proliferation

Area of Science:

• Endocrinology and Metabolic Diseases
• Pharmacology and Drug Discovery
• Cell Biology

Background:

• Diabetes mellitus is characterized by insufficient pancreatic beta-cell mass or function.
• Current treatments focus on insulin secretion, lacking agents to increase human beta-cell replication.
• Restoring beta-cell mass is a key therapeutic goal for diabetes.

Purpose of the Study:

• To identify pharmacological agents that stimulate beta-cell proliferation in humans.
• To investigate the mechanism of action for novel beta-cell regenerative compounds.
• To evaluate the therapeutic potential of these compounds in preclinical models of diabetes.

Main Methods:

• Screening of aminopyrazine compounds for beta-cell proliferation.
• In vitro studies using adult primary human islets.
• In vivo studies involving transplantation into diabetic mice and oral administration.
• Biochemical, genetic, and cell biology analyses to identify molecular targets.

Main Results:

• Aminopyrazine compounds were found to stimulate robust beta-cell proliferation in human islets.
• These compounds likely act through combined inhibition of DYRK1A (Dual-specificity Tyrosine Phosphorylation-Regulated Kinase 1A) and GSK3B (Glycogen Synthase Kinase 3 Beta).
• Treated human islets maintained functionality in vitro and after transplantation.
• Oral administration in diabetic mice increased beta-cell proliferation and mass, improved insulin content, and enhanced glycemic control.
• Dyrk1a was identified as a key molecular target.

Conclusions:

• Aminopyrazine compounds show promise for stimulating beta-cell regeneration.
• This study demonstrates the feasibility of an oral therapy to restore beta-cell mass in diabetes.
• The identified pathway provides a tractable target for future diabetes drug discovery efforts.